Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28974480 | 0.98 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL27790382 | 0.98 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL28154440 | 0.91 | — | — | |
| SCHEMBL22652946 | 0.91 | — | — | |
| SCHEMBL516829 | 0.91 | — | — | |
| SCHEMBL23745320 | 0.91 | — | — | |
| SCHEMBL18211893 | 0.88 | — | — | |
| SCHEMBL16877579 | 0.88 | MEN1 (0.32) | MEN1KMT2AKDM4EGAACYP2C9 | |
| Hydrochloric Acid SCHEMBL21200542 | 0.88 | SLC6A2 (0.31) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16877367 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114105908-A | Preparation method of key intermediate of tetrahydronaphthalene benzamide | 辽宁大学 | 2022-03-01 | — | — | CN | claimed |
| CN-103724269-B | Phenyl 1, 2-isoxazole or phenyl 1, 2-pyrazole compound and application thereof | 中国科学院上海药物研究所 | 2016-12-21 | — | — | CN | claimed |
| CN-118530229-A | Arctigenin derivative and preparation method and application thereof | 深圳市翰林生物医药科技有限公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-112538072-B | Aminopyrimidine EGFR inhibitors | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| CN-114105908-A | Preparation method of key intermediate of tetrahydronaphthalene benzamide | 辽宁大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-108137544-B | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity | 深圳市塔吉瑞生物医药有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-110878070-B | Method for preparing asymmetric urea compound | 中国科学院化学研究所 | 2021-08-31 | — | — | CN | disclosed |
| CN-112538072-A | Novel aminopyrimidine EGFR (epidermal growth factor receptor) inhibitor | 齐鲁制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
| CN-111454218-A | 2,4, 5-substituted pyrimidine compound and preparation method and application thereof | 烟台药物研究所 | 2020-07-28 | — | — | CN | disclosed |
| WO-2020150385-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | CURZA GLOBAL, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| CN-103694163-A | Compounds as Potassium Channel Modulators | SHANGHAI SIMCERE DRUG RES CO LTD | 2014-04-02 | — | — | CN | disclosed |
| CN-103214456-A | Benzimidazole compound with antitumour activity as well as preparation method and application thereof | LANG HENGYUAN | 2013-07-24 | — | — | CN | disclosed |
| CN-102971291-A | Novel amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORP | 2013-03-13 | — | — | CN | disclosed |
| CN-102388051-A | HIV replication inhibitors | BOEHRINGER INGELHEIM INT | 2012-03-21 | — | — | CN | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| CN-102190535-A | Method for synthesizing E-alpha-cyan-4-substituted cinnamate compounds | UNIV EAST CHINA SCIENCE & TECH | 2011-09-21 | — | — | CN | disclosed |
| EP-2142537-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008115973-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-25 | — | — | WO | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | SLC6A2 3080/4885SLC6A4 3119/4885SLC6A3 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.